DDW Highlights: 18 November 2024
The Drug Discovery World Podcast
The latest episode of the is now available to listen to. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the Society for Immunotherapy of Cancer (SITC) 2024 taking place in Houston recently, there have been a number of recent announcements regarding the clinical advancement of immunocytokines, METTL3 inhibitors, cancer vaccines, CAR-T therapies and immune checkpoint inhibitors for the treatment of cancer. You can listen here, or find The Drug Discovery World Podcast on , and
info_outline
DDW Highlights: 11 November 2024
The Drug Discovery World Podcast
The latest episode of the is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week DDW has reported on significant investment in the development of treatments for neurodegenerative diseases, but also gene therapies for CNS disorders and radioligand-based therapies for cancer. You can listen here, or find The Drug Discovery World Podcast on , and
info_outline
DDW Highlights: 4 November 2024
The Drug Discovery World Podcast
The latest episode of the is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week that saw a second monoclonal antibody rejected by UK regulator NICE, antibodies have been high on the news agenda. More positively, a new indication for Fasenra was approved in the EU, researchers found an antibody platform could overcome the challenges of treating mutating viruses, and monoclonal antibodies showed promise in lung cancer and immunoglobulin A nephropathy. You can listen...
info_outline
How to streamline regulatory approval
The Drug Discovery World Podcast
This is the latest episode of the free DDW narrated podcast, titled "How to streamline regulatory approval", which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: and . In the first article, Ken Forman, Senior Director of Product Strategy, IDBS explains how robust digital workflows can reduce errors and time to compile data leading to greater transparency, faster reporting and help biopharmaceutical companies reach regulatory submission faster. In the second article, Craig Caceci, Managing Director at Terebellum, offers guidance to...
info_outline
DDW Highlights: 29 October 2024
The Drug Discovery World Podcast
The latest episode of the is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With a presidential election just round the corner in the US and a new UK budget on the way, financial support for life sciences is high on the agenda, so the news round-up this week focuses on investment in drug discovery, by private investors, governments and charities. You can listen below, or find The Drug Discovery World Podcast on , and
info_outline
The unmet critical need for concussion drug therapies
The Drug Discovery World Podcast
In theseries, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with CEO of Oxeia, Dr Michael Wyand, where we talk about Oxeia’s work; the unmet critical need for concussion drug therapies; the challenges facing them, including in clinical trials and investment; the potential market for concussion drugs, and more. You can now, and find The Drug Discovery World Podcast on , and
info_outline
DDW Highlights: 22 October 2024
The Drug Discovery World Podcast
The latest episode of the is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we are halfway through , our news highlights this week focus on studies that could advance the treatment of cancer in the future, including a new understanding of cancer drug resistance, and novel therapeutics like radioimmunotherapy, RBM39 degraders and peptide-drug conjugates. You can listen below, or find The Drug Discovery World Podcast on , and
info_outline
DDW Highlights: 15 October 2024
The Drug Discovery World Podcast
The latest episode of the is now available to listen to. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Recently, the Society for Neuroscience's annual meeting took place, so the headlines have been dominated by the latest discoveries related to the brain and the central nervous system, including significant findings related to GLP-1 agonists and an advanced theory of bipolar disorder. If these are of interest, don’t forget to register for on 24 October. You can listen here, or find The Drug Discovery...
info_outline
DDW Highlights: 30 September 2024
The Drug Discovery World Podcast
The latest episode of the is now available. The publication of DDW’s latest eBook on immunotherapy has coincided with some interesting developments in this therapy area, particularly monoclonal antibodies, including two new regulatory approvals. You can listen here, or find The Drug Discovery World Podcast on , and
info_outline
DDW Highlights: 23 September 2024
The Drug Discovery World Podcast
The latest episode of the is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of developments related to cell therapies, particularly CAR-T cell therapies, beyond their traditional use in haematological malignancies. You can listen below, or find The Drug Discovery World Podcast on , and
info_outlineIn the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.
In this episode, Megan Thomas is in conversation with Dr Friso Postma, Vice President of AI Drug Discovery at BioXcel Therapeutics.
Thanks to BioXcel's AI platform, the company was able to repurpose previous drugs to obtain FDA approval for its acute treatment for agitation associated with schizophrenia and bipolar disorder, IGALMI, in April 2022, which was the first drug development success that involved the actual use of AI.
You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.